Previous Article | Next Article ![]()
Infection and Immunity, June 2001, p. 3713-3718, Vol. 69, No. 6
Immunology and Epidemiology Units, Noguchi Memorial
Institute for Medical Research, University of Ghana, Legon,
Ghana1; Centre for Medical Parasitology,
Department of Infectious Diseases, Copenhagen University Hospital
(Rigshospitalet), and Institute for Medical Microbiology and
Immunology, University of Copenhagen, Copenhagen,
Denmark2; and Department of
Biochemistry, University of Khartoum, Khartoum, Sudan3
Received 13 November 2000/Returned for modification 11 January
2001/Accepted 6 March 2001
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a variant antigen expressed on the surface of infected
erythrocytes. Each parasite genome contains about 40 PfEMP1 genes, but
only 1 PfEMP1 gene is expressed at a given time. PfEMP1 serves as a parasite-sequestering ligand to endothelial cells and enables the
parasites to avoid splenic passage. PfEMP1 antibodies may protect from
disease by inhibiting sequestration, thus facilitating the destruction
of infected erythrocytes in the spleen. In this study, we have measured
antibodies in Ghanaian children to a conserved region of PfEMP1 by
enzyme-linked immunosorbent assay and antibodies to variant molecules
on erythrocytes infected with field isolates of P. falciparum by flow cytometry. Based on close clinical monitoring, the children were grouped into those who did (susceptible) and those
who did not (protected) have malaria during the season. The prevalences
of antibodies to both the conserved PfEMP1 peptide and the variant
epitopes were greater than 50%, and the levels of immunoglobulin G
(IgG) correlated with age. The levels of antibodies to both the
conserved peptide and the variant epitopes were higher in protected
than in susceptible children. After correcting for the effect of age,
the levels of IgG to variant antigens on a Sudanese and a Ghanaian
parasite isolate remained significantly higher in protected than in
susceptible children. Thus, the levels of IgG to variant antigens
expressed on the surface of infected erythrocytes correlated with
protection from clinical malaria. In contrast, the levels of IgG to a
peptide derived from a conserved part of PfEMP1 did not correlate with
protection from malaria.
Antibodies directed against the
variant antigen Plasmodium falciparum erythrocyte membrane
protein 1 (PfEMP1) have been suggested to be a key element of malaria
immunity (7, 21, 22). PfEMP1 is encoded by about 40 var genes (3, 27, 32) and mediates sequestration of the parasite to endothelial cells of blood vessels within various host organs including the brain and the placenta (2). Sequestration is probably a strategy evolved by the
parasite to avoid filtration through and killing in the spleen
(12). Sequestration will thus tend to increase parasite
multiplication rates. Furthermore, the process is thought to contribute
to the pathogenesis of severe malaria because the accumulation of
parasites provokes a strong inflammatory response that can be harmful
to the host (4). Antibodies to PfEMP1 can block the
adhesion of mature parasitized erythrocytes to specific receptors
(28), and individuals in malaria-endemic areas acquire
antibodies that block parasite adhesion (17, 25, 26). Such
antibodies may contribute to protection against malaria by reducing
tissue-specific sequestration and inflammation and by reducing the
parasite burden as nonbinding parasites are removed in the spleen.
These protective mechanisms are not mutually exclusive, but the first
will tend to reduce the number of severe infections whereas the second
will tend to reduce the number of fever episodes, which occur as the parasite density increases above the fever threshold. It has been shown
that development of malaria severe enough to warrant hospital admission
is associated with lack of antibody reactivity to the variant antigens
expressed by the parasite isolate causing the disease (7).
The present study was designed to test whether antibodies to variant
antigens are involved in protection of children from febrile malaria
episodes. Ghanaian children have asymptomatic parasitemia controlled at
relatively low densities most of the time. The first symptom of malaria
in these children usually is fever, which occurs when parasite
densities exceed the fever threshold because of insufficient control of
parasite multiplication. In this study children were closely monitored
clinically and parasitologically during the malaria season and
subsequently divided into two groups consisting of those who did and
those who did not develop malaria. We show that the levels in plasma of
antibodies to variant antigens expressed on some parasite isolates
before the malaria season were associated with protection against
febrile malaria episodes.
Study area, study population, and clinical
surveillance.
The study was conducted in Dodowa, a semirural town
outside Accra, Ghana. Malaria transmission is perennial but peaks
during or immediately after the major rainy season and is lowest during the preceding dry season. The estimated number of infective bites per
year is around 20, and about 80% of these are received during the
major malaria season. Most infections (98%) are due to P. falciparum (1). Dodowa can thus be described as an
area of hyperendemic, seasonal malaria transmission. In the present
study, we studied a random subpopulation consisting of 118 sicklecell trait-negative children (age range, 3 to 15 years) drawn from a larger
cohort of 300 children described in detail previously (13). The children in the study cohort were monitored by
active and passive case detection between April and November 1994 (13). Heparinized venous blood samples were obtained in
April 1994 (preseason) and November 1994 (postseason). Plasma samples
were stored at Antibody Measurements. (i) Antibody reactivity to variant antigen
expressed on the surface of infected erythrocytes.
The levels of
antibodies to five different parasite isolates were measured by flow
cytometry (29). We used primary isolates L73 and L50,
obtained from two asymptomatic children within the Ghanaian cohort; the
Busua isolate, obtained from a Danish patient who contracted malaria
while in another region in Ghana; and 2D3 and G12, obtained from
Sudanese malaria patients. The parasite isolates were maintained in
culture for up to 3 weeks before being assayed by standard procedures
with slight modifications (11, 33). On the day of the
assay, erythrocytes infected with mature blood stages were purified by
exposure to a strong magnetic field, resulting in material having
>75% parasitemia (29). Aliquots of 2 × 105 purified late-stage-infected erythrocytes labeled-with
ethidium bromide were sequentially exposed to 20 µl of plasma
previously adsorbed with 106 uninfected type O
erythrocytes, 0.5 µl of goat anti-human immunoglobulin G (IgG) (Dako,
Glostrup, Denmark), and 4 µl of fluorescein isothiocyanate-conjugated rabbit anti-goat IgG (Dako). Samples were washed twice in
phosphate-buffered saline between each incubation step and analyzed on
a Coulter EPICS XL-MCL flow cytometer (Coulter Electronics, Luton,
United Kingdom) using WinMDI software
(http://facs.scripps.edu/software.html). For each plasma sample, the
mean late-stage-infected erythrocyte fluorescein isothiocyanate
fluorescence index was recorded. Nonspecific labeling was evaluated by
analysis of uninfected erythrocytes. A positive control pool from six
residents of Dodowa was titrated and included with each parasite
isolate assayed. For quantification, mean fluorescence index units were
transformed to antibody units by using standard curves generated from
the titrated plasma pool, for which the highest value was arbitrarily
assigned 1,000 units. The lower limit of positivity was determined as
values greater than the mean obtained with the plasma of 12 unexposed
Danish donors plus 2 standard deviations. It has previously been shown that the main reactivity measured in this assay is directed against large (200- to 300-kDa) polymorphic surface-expressed molecules (29) and depends on expression of PfEMP1
(24).
(ii) Antibody reactivity to the synthetic peptide.
A
conserved linear peptide from the published sequence of the
var-1 gene of the Malayan Camp (MC) isolate
(32) was obtained from Schaefer Co. (Copenhagen, Denmark).
The amino acid sequence was DIGDIVRGKDLY (MCvar-1 amino
acids 183 to 194). The purity of the peptide was greater than 95%.
Antibody reactivity was measured by an enzyme-linked immunosorbent
assay as previously described (31). To account for
day-to-day variation, the results were calculated as relative optical
density at 492 nm (OD): (ODsample Statistical analysis.
Statistical analysis was done using
the Sigma Stat software package (Jandel Scientific, San Rafael,
Calif.). The P. falciparum infections in the study cohort.
All
118 children in the cohort were parasitemic at one or more of the
monthly parasite screenings done to determine the parasite point
prevalence, which fluctuated around 50% throughout the 8-month duration of the clinical surveillance (13). Based on this
surveillance, which included a combination of active- and passive-case
detection (13) we divided the children into two groups.
During the period of surveillance, 27 children had at least one episode
with fever in the presence of asexual parasitemia of >5,000/µl, and
these children were considered susceptible to malaria (group 1); 73 children who did not have episodes of measured or reported fever in the
presence of asexual parasitemia were considered to be clinically protected (group 2). A group of 18 children who had episodes of measured or reported fevers in the presence of asexual parasitemia of
<5,000/µl were excluded from the analysis, since it is unclear whether fever episodes in the presence of low-grade parasitemia were
due to malaria, when asymptomatic parasitemia is common.
IgG recognition of the variant antigens and the conserved peptide
sequence.
In the Ghanaian children the prevalence of IgG to
variant antigens of parasite isolates from Ghana (L73, L50, and Busua)
or Sudan (G12 and 2D3) and the prevalence of IgG to the PfEMP1 peptide from the relatively conserved Duffy binding-like region 1 (DBL1) were
higher than 50% (Fig. 1A). This shows
that the majority of the children had antibodies to both variant
antigens on the surface of infected erythrocytes and to the peptide
from the relatively conserved part of PfEMP1.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3713-3718.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Antibodies to Variant Antigens on the Surfaces of
Infected Erythrocytes Are Associated with Protection from Malaria
in Ghanaian Children
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
20°C until analysis. Control plasma samples were
obtained from healthy Danish adults who had never lived in a
malaria-endemic area. A pool of plasma obtained from adults living in
Dodowa and selected for high antibody reactivity to variant surface
antigens was used as positive control. Informed consent was obtained
from all studied individuals and/or their parents. The Ghanaian
Ministry of Health approved the study.
ODbackground)/(ODpositive control
ODbackground). A pool of plasma samples obtained from
six adults living in Dodowa previously shown to react strongly with the
peptide was used as positive control. The lower limit of positivity was
determined as the mean relative OD of the plasma of 31 unexposed Danish
donors plus 2 standard deviations.
2 test was used to compare proportions of
antibody responders in protected and unprotected children, while the
Mann-Whitney tests for paired and unpaired data were used to compare
the antibody levels between groups. Spearman's rank correlation test
was used to correlate antibody responses in pre- and post-malaria
transmission season samples and to assess associations between antibody
levels and age. Two-way analysis of variance was used to compare
antibody responses stratified by age groups among the
malaria-susceptible or -protected children. RSEPT
(http://www.ci.tuwien.ac.at/R/bin/windows/windows/Rsept.zip) statistical software was used to perform multiple-regression analysis to correct for the confounding effects of age. Differences were considered statistically significant if P < 0.05.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (21K):
[in a new window]
FIG. 1.
(A) Prevalence and 95% confidence interval (C.I.) of
IgG antibody to variant antigens on the surface of erythrocytes
infected with Ghanaian parasite isolates (L73, L50, and Busua) or
Sudanese isolates (Sd-2D3 and G12) and to a peptide corresponding to a
conserved part of PfEMP1 in premalaria season plasma from Ghanaian
children. (B) Levels (median units and 95% confidence interval) of IgG
to variant antigens on parasites from Ghana or Sudan in premalaria
season plasma samples from Ghanaian children. Open bars indicate
malaria-susceptible individuals, and hatched bars represent individuals
protected from malaria.
Antibody levels and protection from malaria.
For all parasite
isolates tested, the preseason levels of antibodies in the protected
(group 2) children were higher than in the susceptible (group 1)
children (Fig. 1B). However, the responses increased with age
[rs, < 0.6 ; P(rs) < 0.001], and since the protected children were older than the
susceptible children, comparisons between antibody levels in the two
groups of children had to be corrected for age (Fig. 2A to
D). Figure 2E to H shows the
age-corrected levels of antibodies. Of the parasite isolates tested,
the antibody levels against Busua and G12 were significantly higher in
the protected children than in the susceptible children (P = 0.046 and P = 0.006, respectively). After age
correction, the mean level of reactivity for G12 was approximately
twice as high in the protected children as in the susceptible children (Fig. 2G). The difference between susceptible and protected children was most pronounced in the age groups from 6 to 9 years and from 10 to
15 years (Fig. 2C). This is consistent with clinical and parasitological data on the cohort, indicating that most of the protection from febrile disease is acquired after 7 years of age. The
age-corrected levels for the Ghanaian isolate L50 (Fig. 2A and E),
which did not differ significantly between the groups, are shown for
comparison.
|
Correlation of responses at different measurements in the same
individual.
The bulk of transmission, about 20 infective bites per
person, is concentrated in the major malaria transmission season.
During this period, most individuals are likely to be challenged by
"new" parasites, i.e., parasites that are antigenically different
from those carried in many individuals with asymptomatic parasitemia outside the transmission season. To test whether new antigenic challenges would boost antibody levels, we compared the reactivity to
two isolates (L50 and Busua) in matched samples collected at the
beginning and end of the transmission season. In both protected and
susceptible children, the median levels of antibodies against both
isolates increased (Fig. 3) (L50,
P < 0.001; Busua, P = 0.03) during the
malaria season.
|
| |
DISCUSSION |
|---|
|
|
|---|
Malaria immunity is slowly acquired by individuals living in areas of stable malaria transmission (9). Immunity is partial, since adults living in areas of highly endemic infection often have low-density parasitemia (5) and occasionally experience malaria fevers, which occur when the parasite densities increase over about 1,000 to 2,000 parasites/µl (23). These and other data strongly suggest that the immunoeffector mechanisms responsible for protection are mediated by antibodies (10) directed against the erythrocytic stages of the parasite. It has been debated whether the targets of these antigens are conserved proteins expressed on the surface of merozoites (15) or variant antigens on the surface of infected erythrocytes (21, 30).
The main finding of this study is that Ghanaian children with high levels in plasma of antibody to variant antigens during the premalaria season were less likely to contract malaria during the subsequent malaria season than were children with low levels of such antibodies. This association was found for two (G12 and Busua) of the five isolates tested. For one of the isolates, the P value was so low that it is unlikely that the association occurred by chance due to multiple comparisons. The most likely explanation for these observations is that during the malaria season the children were exposed to parasites expressing PfEMP1 variants that serologically cross-react with G12 and Busua and that those with high levels of antibodies against these parasites were protected from disease. However, the possibility that the levels of antibodies to G12 and Busua were associated with the levels of antibodies to other variant or conserved malaria antigens, which in turn mediated the protective effect, cannot be excluded in this type of immunoepidemiological study. In any case, our data are in concordance with those of other studies that have indicated the importance of antibodies to variant antigens for protection against both severe (7) and uncomplicated (20, 22) malaria. In the present study, the strongest correlate of protection was antibody reactivity to variant surface antigens expressed by the Sudanese parasite isolate G12. A similar study conducted in the Sudan showed correlation between protection and the presence of antibodies to the Ghanaian parasite isolate L73 (20). The reason why antibodies to the serotype expressed by the Ghanaian parasite were associated with protection in Sudan while antibodies to the serotype expressed by the Sudanese parasite were associated with protection in Ghana is obscure. It could be a coincidence, but these parasites possibly expressed "suitably common" serotypes. That is, the parasites were common enough to allow a large number of the cohort members in Sudan and Ghana to be exposed to them during the follow-up but not so common that all individuals already had developed immunity to them before the study. Alternatively, the presence of antibodies against an isolate derived from the other side of the African continent may be an indicator that the donor had a broad range of PfEMP1 antibodies and therefore was protected against challenge by parasites carrying a broad range of antigenic types.
For all the assays the median level of reactivity was higher in protected than in susceptible children, but age was a confounding factor, and after age correction the antibody levels to the variant antigens on three of the isolates and the conserved PfEMP1 peptide were comparable between the two groups. It is not surprising that an association between protection and antibody reactivity was not detectable for all isolates. Even if antibody to an isolate conveys protection, associations between susceptibility to malaria and antibody levels can be detected only if a sizeable fraction of children during the follow-up are challenged with new parasites carrying variants that serologically overlap with the isolates used for the assays.
A limited number of parasite-derived antigens are expressed on the surface of erythrocytes infected by late developmental stages of P. falciparum. The best characterized of these is the variant molecule PfEMP1. The PfEMP1 repertoire is very diverse, and little is known about which parts of the native 200- to 300-kDa molecule are accessible to antibodies when it is expressed on the surface of erythrocytes. This has made it difficult to base measurements of antibody responses to the variable parts of the molecule on recombinant products or synthetic peptides. Instead, most studies have used agglutination assays (6, 7, 19, 22) or flow cytometry-based measurements (18, 20, 24). The flow cytometry assay used in this study detects isolate specific antibodies of a similar molecular weight to PfEMP1 (29), and plasma from malaria-immune individuals does not react in the assay if the parasite isolate used does not express PfEMP1 (24). Furthermore, there is a strong correlation between the ability of individual plasmas to recognize parasite isolates in agglutination assays and in the flow cytometry-based method (29). Therefore, we believe that most of the antibodies detected by the flow cytometry assay used in this study are directed against PfEMP1, but we cannot rule out the possibility that some are directed against other surface-expressed parasite molecules such as the rifins (8, 16). Our data show that the levels of antibody to variant antigens generally were higher in postseason samples than in preseason samples. This seasonal effect was seen in samples from both protected and susceptible children. The effect was more pronounced for the levels of antibody to the L50 isolate than for those to the Busua isolate, which may reflect the fact that the antigenic type carried by L50 was the more common of the two and that individuals are therefore more likely to be exposed to parasites cross-reactive with L50 during the transmission.
We did not find any correlation between protection and antibody response to the conserved PfEMP1 peptide epitope originating from the DBL1 domain of PfEMP1. In a study from Sudan (31), higher levels of IgG to the same peptide epitope were found in asymptomatically infected individuals than in those with malaria, but in that study it was impossible to discriminate between the effects of age and protection. Later studies indicated that the conserved DBL1 region used in the present study is not accessible for antibodies on the surface of infected erythrocytes (T. Staalsoe, unpublished results).
In conclusion, we found an association between the levels of IgG to variant antigens on infected erythrocytes and protection from malaria in Ghanaian children, but not for the antibody levels to the conserved peptide from the DBL1 domain of PfEMP1. The data indicate that antibodies against a broadening range of variant antigens are important for protection against febrile malaria episodes in Ghanaian children who are in the process of acquiring malaria immunity. The data also support the notion that antibodies against variant antigens are involved in controlling parasite multiplication and maintaining parasitemia at levels below the fever threshold. Our data do not exclude the possibility that antibodies against conserved epitopes play a role in malaria immunity. Indeed, we have previously found an association between the levels of antibodies against glutamine-rich protein and protection using the same cohort of children (14). By reducing the parasite multiplication rate, such antibodies may extend the period available for the immune system to produce antibodies against new PfEMP1 variants before they cause symptoms.
| |
ACKNOWLEDGMENTS |
|---|
Ben Abuakwa, Gitte Pedersen, and Anne Corfitz are thanked for technical assistance. We are grateful to the children of Dodowa for donating blood samples for analysis.
The study received financial support from the Danish International Development Agency and the Fifth Framework Programme of The European Commission.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institute of Medical Microbiology and Immunology, University of Copenhagen, Panum Institute Building 24.2, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. Phone: 45 35 32 76 77. Fax: 45 35 32 78 51. E-mail: theander{at}biobase.dk.
Editor: J. M. Mansfield
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Afari, E. A., M. Appawu, S. Dunyo, A. Baffoe-Wilmot, and F. K. Nkrumah. 1995. Malaria infection, morbidity and transmission in two ecological zones in southern Ghana. Afr. J. Health Sci. 2:312-316[Medline]. |
| 2. |
Baruch, D. I.,
J. A. Gormley,
C. Ma,
R. J. Howard, and B. L. Pasloske.
1996.
Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.
Proc. Natl. Acad. Sci. USA
93:3497-3502 |
| 3. | Baruch, D. I., B. L. Pasloske, H. B. Singh, X. Bi, X. C. Ma, M. Feldman, T. F. Taraschi, and R. J. Howard. 1995. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82:77-87[CrossRef][Medline]. |
| 4. | Berendt, A. R., G. D. H. Turner, and C. I. Newbold. 1994. Cerebral malaria: the sequestration hypothesis. Parasitol. Today 10:412-414[CrossRef][Medline]. |
| 5. | Bruce-Chwatt, L. J. 1963. A longitudinal survey of natural malaria infection in a group of West African adults. W. Afr. Med. J. 12:141-173. |
| 6. | Bull, P. C., M. Kortok, O. Kai, F. Ndungu, A. Ross, B. S. Lowe, C. I. Newbold, and K. Marsh. 2000. Plasmodium falciparum-infected erythrocytes: agglutination by diverse Kenyan plasma is associated with severe disease and young host age. J. Infect. Dis. 182:252-259[CrossRef][Medline]. (Erratum, 182:641.) |
| 7. | Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold, and K. Marsh. 1998. Parasite antigens on the infected red cell are targets for naturally acquired immunity to malaria. Nat. Med. 4:358-360[CrossRef][Medline]. |
| 8. | Cheng, Q., N. Cloonan, K. Fischer, J. Thompson, G. Waine, M. Lanzer, and A. Saul. 1998. Stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol. Biochem. Parasitol. 97:161-176[CrossRef][Medline]. |
| 9. | Christophers, S. R. 1924. The mechanism of immunity against malaria in communities living under hyper-endemic conditions. Indian J. Med. Res. 12:273-294. |
| 10. | Cohen, S., I. A. McGregor, and S. Carrington. 1961. Gammaglobulin and acquired immunity to human malaria. Nature 192:733-737[CrossRef][Medline]. |
| 11. | Cranmer, S. L., C. Magowan, J. Liang, R. L. Coppel, and B. M. Cooke. 1997. An alternative to serum for cultivation of Plasmodium falciparum in vitro. Trans. R. Soc. Trop. Med. Hyg. 91:363-365[CrossRef][Medline]. |
| 12. |
David, P. H.,
M. Hommel,
L. H. Miller,
I. J. Udeinya, and L. D. Oligino.
1983.
Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes.
Proc. Natl. Acad. Sci. USA
80:5075-5079 |
| 13. |
Dodoo, D.,
T. G. Theander,
J. A. L. Kurtzhals,
K. Koram,
E. Riley,
B. D. Akanmori,
F. K. Nkrumah, and L. Hviid.
1999.
Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with clinical protection from malaria.
Infect. Immun.
67:2131-2137 |
| 14. | Dodoo, D., M. Theisen, J. A. Kurtzhals, B. D. Akanmori, K. A. Koram, S. Jepsen, F. K. Nkrumah, T. G. Theander, and L. Hviid. 2000. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J. Infect. Dis. 181:1202-1205[CrossRef][Medline]. |
| 15. | Druilhe, P., and J.-L. Perignon. 1997. A hypothesis about the chronicity of malaria infection. Parasitol. Today 13:353-357[CrossRef][Medline]. |
| 16. |
Fernandez, V.,
M. Hommel,
Q. J. Chen,
P. Hagblom, and M. Wahlgren.
1999.
Small, clonally variant antigens expressed on the surface of the Plasmodium falciparum-infected erythrocyte are encoded by the rif gene family and are the target of human immune responses.
J. Exp. Med.
190:1393-1403 |
| 17. | Fried, M., F. Nosten, A. Brockman, B. T. Brabin, and P. E. Duffy. 1998. Maternal antibodies block malaria. Nature 395:851-852[CrossRef][Medline]. |
| 18. |
Giha, H. A.,
T. Staalsoe,
D. Dodoo,
I. M. Elhassan,
C. Roper,
G. M. Satti,
D. E. Arnot,
T. G. Theander, and L. Hviid.
1999.
Nine-year longitudinal study of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes.
Infect. Immun.
67:4092-4098 |
| 19. | Giha, H. A., T. Staalsoe, D. Dodoo, I. M. Elhassan, C. Roper, G. M. H. Satti, D. E. Arnot, L. Hviid, and T. G. Theander. 1999. Overlapping antigenic repertoires of variant antigens expressed on the surface of erythrocytes infected by Plasmodium falciparum. Parasitology 119:7-17. |
| 20. | Giha, H. A., T. Staalsoe, D. Dodoo, C. Roper, G. M. Satti, D. E. Arnot, L. Hviid, and T. G. Theander. 2000. Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol. Lett. 71:117-126[CrossRef][Medline]. |
| 21. |
Marsh, K., and R. J. Howard.
1986.
Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants.
Science
231:150-153 |
| 22. | Marsh, K., L. Otoo, R. J. Hayes, D. C. Carson, and B. M. Greenwood. 1989. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83:293-303[CrossRef][Medline]. |
| 23. | Miller, M. J. 1958. Observations on the natural history of malaria in the semi-resistant West African. Trans. R. Soc. Trop. Med. Hyg. 52:152-168. |
| 24. | Piper, K. P., D. J. Roberts, and K. P. Day. 1999. Plasmodium falciparum: analysis of the antibody specificity to the surface of the trophozoite-infected erythrocyte. Exp. Parasitol. 91:161-169[CrossRef][Medline]. |
| 25. |
Ricke, C. H.,
T. Staalsoe,
K. Koram,
B. D. Akanmori,
E. M. Riley,
T. G. Theander, and L. Hviid.
2000.
Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A.
J. Immunol.
165:3309-3316 |
| 26. | Singh, B., M. Ho, S. Looareesuwan, E. Mathai, D. A. Warrell, and M. Hommel. 1988. Plasmodium falciparum: inhibition/reversal of cytoadherence of Thai isolates to melanoma cells by local immune sera. Clin. Exp. Immunol. 72:145-150[Medline]. |
| 27. | Smith, J. D., C. E. Chitnis, A. G. Craig, D. J. Roberts, D. E. Hudson-Taylor, D. S. Peterson, R. Pinches, C. I. Newbold, and L. H. Miller. 1995. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82:101-110[CrossRef][Medline]. |
| 28. |
Smith, J. D.,
A. G. Craig,
N. Kriek,
D. Hudson-Taylor,
S. Kyes,
T. Fagen,
R. Pinches,
D. I. Baruch,
C. I. Newbold, and L. H. Miller.
2000.
Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: a parasite adhesion trait implicated in cerebral malaria.
Proc. Natl. Acad. Sci. USA
97:1766-1771 |
| 29. | Staalsoe, T., H. A. Giha, D. Dodoo, T. G. Theander, and L. Hviid. 1999. Detection of antibodies to variant antigens on Plasmodium falciparum infected erythrocytes by flow cytometry. Cytometry 35:329-336[CrossRef][Medline]. |
| 30. | Staalsoe, T., and L. Hviid. 1998. The role of variant-specific immunity in asymptomatic infections: maintaining a fine balance. Parasitol. Today 14:177-178. |
| 31. | Staalsø, T., E. A. G. Khalil, I. M. Elhassan, E. E. Zijlstra, A. M. Elhassan, H. A. Giha, T. G. Theander, and P. H. Jakobsen. 1998. Antibody reactivity to conserved linear epitopes of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). Immunol. Lett. 60:121-126[CrossRef][Medline]. |
| 32. | Su, X., V. M. Heatwole, S. P. Wertheimer, F. Guinet, J. A. Herrfeldt, D. S. Peterson, J. A. Ravetch, and T. E. Wellems. 1995. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes Cell 82:89-100[CrossRef][Medline]. |
| 33. |
Trager, W., and J. B. Jensen.
1976.
Human malaria parasites in continuous culture.
Science
193:673-675 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»